Why the study?
Does heparin half-life and sensitivity differ between patients with deep vein thrombosis and healthy volunteers?
Does heparin half-life and sensitivity differ between patients with deep vein thrombosis and healthy volunteers?
The phenomenon of heparin hyperconsumption reflects individual patient characteristics rather than the presence of deep vein thrombosis, and has no diagnostic value.
Answers are grounded in this paper and cite their sources.
Heparin dosing should not assume DVT-related differences; leaves open whether patient-specific factors better guide monitoring than disease status.
In some patients affected with deep vein thrombosis (DVT) it is necessary to administer large doses of heparin to achieve proper anticoagulation. To investigate the clinical relevance of this phenomenon, we studied the heparin half-life and the heparin sensitivity after a bolus IV injection of 60 i.u. kg-1 in seven healthy volunteers and eight DVT patients investigated on day 1 or 2 and again between day 10 and 20 of the heparin therapy. The heparin half-life, the in vitro and ex vivo heparin sensitivity, were comparable in the healthy volunteers and in the patients at both times of investigation. However, there were large interindividual variations in the controls and in the patients, not correlated to the levels of any coagulation factors. Thus, the heparin hyperconsumption phenomenon occasionally observed in a given patient reflected individual characteristics and was no value in the diagnosis of DVT.
No takes yet. Share an insight, caveat, or question.
Benchekroun et al. (1986) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: